Treatment costs of Parkinson’s disease in Central Europe

Simple item page
dc.contributor.authorMarešová, Petra
dc.contributor.authorKlímová, Blanka
dc.contributor.authorVališ, Martin
dc.contributor.authorKuča, Kamil
dc.contributor.authorMohelská, Hana
dc.contributor.otherEkonomická fakultacs
dc.date.accessioned2016-09-23
dc.date.available2016-09-23
dc.date.defense2016-09-23
dc.description.abstractThe aim of the study is to describe current values of direct costs of Parkinson’s disease in western and central Europe in comparison with other available data in order to illustrate the development of the treatment costs of Parkinson’s disease (PD) on the public sector. In this research study Drummond’s methodology is used for the specification of costs. The costs are divided into two categories. The first category consists of the costs of creation and running of health care program and these costs are perceived as the used sources. The costs are calculated on the basis of the reviews of the studies from the European countries, but also on the basis of authors’ own survey in the University Hospital of Hradec Kralove conducted among 510 patients in the period of 2011-to the third quarter of 2015. Within this study the direct costs among 510 patients at the University Hospital of Hradec Kralove were explored in the period of 2011- to the third quarter of 2015. These costs included neurological examination, CT screening, blood collection, hospitalization, and drugs. The total direct costs of patient per year reached 2,032 €. The survey showed that the underpinning of patients with PD was beneficial from the costs point of view because the costs on the outpatient care were much lower in comparison with the inpatient care. In addition, patients released from the hospital are usually transferred to the establishments with subsequent care, for example into hospices, because family care due to its complexity is impossible.en
dc.formattext
dc.format.extent31-39 s.cs
dc.identifier.doi10.15240/tul/001/2016-3-003
dc.identifier.eissn2336-5604
dc.identifier.issn12123609
dc.identifier.urihttps://dspace.tul.cz/handle/15240/18190
dc.language.isoen
dc.publisherTechnická Univerzita v Libercics
dc.publisherTechnical university of Liberec, Czech Republicen
dc.publisher.abbreviationTUL
dc.relation.isbasedonAndlin-Sobocki, P., Jönsson, B., Wittchen, H.-U., & Olesen, J. (2005). Cost of disorders of the brain in Europe. European Journal of Neurology, 12 Suppl 1, 1-27. doi:10.1111/j.1468-1331.2005.01202.x.
dc.relation.isbasedonBarták, M., & Gavúrová, B. (2014). Economics and social aspects of long-term care in the context of the Czech Republic and the Slovak Republic EU membership. In Proceedings of 12th International scientific conference: Economic Policy in the European Union member countries, PTS I and II. (Vol. 2015, pp. 35-44.). Ostravice, Czech Republic.
dc.relation.isbasedonDlouhý, M., & Barták, M. (2013). Mental Health Financing in Six Eastern European Countries. E&M Ekonomie a Management, 16(4), 4-13.
dc.relation.isbasedonDorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., Kieburtz, K., Tanner, C. M. (2007). Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology, 68(5), 384-386. doi:10.1212/01.wnl.0000247740.47667.03.
dc.relation.isbasedonDrummond, M. F., & O’Brien, B. J. (1997). Methods for the Economic Evaluation of Health Care Programs (2nd ed.). Oxford Medical Publication.
dc.relation.isbasedonEuropean Parkinson’s Disease Association. (2015). About Parkinson’s. Retrieved July 8, 2015, from http://www.epda.eu.com/en/pd-info/about-parkinsons/.
dc.relation.isbasedonFarlow, M. R., Schmitt, F., Aarsland, D., Grossberg, G. T., Somogyi, M., & Meng, X. (2013). Comparing Clinical Profiles in Alzheimer’s Disease and Parkinson’s Disease Dementia. Dementia and Geriatric Cognitive Disorders Extra, 3(1), 281-290. doi:10.1159/000351861.
dc.relation.isbasedonFindley, L., Aujla, M., Bain, P. G., Baker, M., Beech, C., Bowman, C., Playfer, J. R. (2003). Direct economic impact of Parkinson’s disease: A research survey in the United Kingdom. Movement Disorders, 18(10), 1139-1145. doi:10.1002/mds.10507.
dc.relation.isbasedonGavurová, B., Vagašová, T. (2016). Regional differences of standardised mortality rates for ischemic heart diseases in the Slovak Republic for the period 1996-2013 in the context of income inequality. Health Economics Review, 6(21),
dc.relation.isbasedonHagell, P., Nordling, S., Reimer, J., Grabowski, M., & Persson, U. (2002). Resource use and costs in a Swedish cohort of patients with Parkinson’s disease. Movement Disorders, 17(6), 1213-1220. doi:10.1002/mds.10262.
dc.relation.isbasedonKlimova, B., & Kuca, K. (2015). Alzheimer’s disease: Potential preventive, non-invasive, intervention strategies in lowering the risk of cognitive decline – A review study. Journal of Applied Biomedicine, 13(4), 257-261. doi:10.1016/j.jab.2015.07.004.
dc.relation.isbasedonKlimova, B., Maresova, P., Valis, M., Hort, J., & Kuca, K. (2015). Alzheimer’s disease and language impairments: social intervention and medical treatment. Clinical Interventions in Aging, 10, 1401-1408. doi:10.2147/CIA.S89714.
dc.relation.isbasedonMaresova, P., Klimova, B., & Kuca, K. (2014). Alzheimers disease: cost cuts call for novel drugs development and national strategy. Ceska a Slovenska Farmacie, 64(1-2), 25-30.
dc.relation.isbasedonMaresova, P., Mohelska, H., Dolejs, J., & Kuca, K. (2015). Socio-economic Aspects of Alzheimer’s Disease. Current Alzheimer Research, 12(9), 903-911.
dc.relation.isbasedonRansmayr, G. (2015). Cognitive impairment in Parkinson’s disease. Psychiatria Danubina, 27(4), 458-461.
dc.relation.isbasedonRůžička, E., Roth, J., & Kaňovský, P. (2000). Parkinsonova nemoc a parkinsonské syndromy [Parkinson’s disease and parkinsonian syndromes]. Praha: Galén.
dc.relation.isbasedonSpottke, A. E., Reuter, M., Machat, O., Bornschein, B., Campenhausen, S. von, Berger, K., Dodel, D. R. (2005). Cost of illness and its predictors for Parkinson’s disease in Germany. PharmacoEconomics, 23(8), 817-836. doi:10.2165/00019053-200523080-00007.
dc.relation.isbasedonvon Campenhausen, S., Winter, Y., Rodrigues e Silva, A., Sampaio, C., Ruzicka, E., Barone, P., Reese, J. P. (2011). Costs of illness and care in Parkinson’s disease: an evaluation in six countries. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 21(2), 180-191. doi:10.1016/j.euroneuro.2010.08.002.
dc.relation.isbasedonVšeobecná Zdravotní Pojišťovna [General Health Insurance Company]. (2015). Retrieved September 8, 2015, from https://www.vzp.cz/o-nas/aktuality/.
dc.relation.isbasedonWinter, Y., von Campenhausen, S. von, Brozova, H., Skoupa, J., Reese, J. P., Bötzel, K., Ruzicka, E. (2010). Costs of Parkinson’s disease in Eastern Europe: A Czech cohort study. Parkinsonism & Related Disorders, 16(1), 51-56. doi:10.1016/j.parkreldis.2009.07.005.
dc.relation.isbasedonYorkston, K. M., Beukelman, D., Strand, E. A., & Bell, K. R. (1999). Management of Motor Speech Disorders in Children and Adults (2nd ed.). Austin, Tex: Pro ed.
dc.relation.isbasedonŠoltés, V., Gavurová, B. (2014). The possibilities of day surgery system development within the health policy in Slovakia. Health Economics Review, 4(35).
dc.relation.ispartofEkonomie a Managementcs
dc.relation.ispartofEconomics and Managementen
dc.relation.isrefereedtrue
dc.rightsCC BY-NC
dc.subjectParkinson’s diseaseen
dc.subjectdirect costsen
dc.subjecttreatmenten
dc.subjectEuropeen
dc.subject.classificationI12
dc.titleTreatment costs of Parkinson’s disease in Central Europeen
dc.typeArticleen
local.accessopen
local.citation.epage39
local.citation.spage31
local.facultyFaculty of Economics
local.fulltextyes
local.relation.abbreviationE&Men
local.relation.abbreviationE+Mcs
local.relation.issue3
local.relation.volume19
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
EM_3_2016_3.pdf
Size:
1.07 MB
Format:
Adobe Portable Document Format
Description:
Článek
Download
Collections
Číslo 3